View in EDS

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.

Saved in:
Bibliographic Details
Title: Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.
Authors: Bellon, J.R.1 (AUTHOR), Tayob, N.2 (AUTHOR), Burstein, H.J.2 (AUTHOR), Partridge, A.3 (AUTHOR), Demeo, M.K.2 (AUTHOR), Tralins, J.2 (AUTHOR), Yang, D.D.4 (AUTHOR), Dang, C.5 (AUTHOR), Isakoff, S.J.6 (AUTHOR), Yardley, D.7 (AUTHOR), Valero, V.8 (AUTHOR), Winer, E.2 (AUTHOR), Krop, I.2 (AUTHOR), Tolaney, S.2 (AUTHOR)
Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pS34-S34. 1p.
Subjects: HER2 positive breast cancer, Hormone receptors, Breast cancer
Abstract: Purpose/objective(s): Anti-HER2 therapy improves local control in women with HER2+ breast cancer. This retrospective analysis evaluates the efficacy and safety of radiation therapy (RT) across a range of RT doses, targets, and schedules among patients receiving T-DM1 and TH in the ATEMPT trial.Materials/methods: The ATEMPT trial is a prospective randomized phase II study of adjuvant ado-trastuzumab emtansine (T-DM1) vs. paclitaxel (T) and trastuzumab (H) following either mastectomy (M) or breast conserving surgery (BCS) in women with stage I HER2+ breast cancer. Eligible patients had T1N0 or T1N1mi HER2+ disease (3+ IHC or FISH ≥ 2) and were randomized 3:1 to either T-DM1 (3.6 mg/kg every three weeks x 17 treatments) or T (80 mg/m2 weekly for 3 weeks), H (4 mg/kg first week, then 2 mg/kg weekly x 12 weeks during T; then 6 mg/kg every 3 weeks x 39 weeks). Breast RT was required following BCS and permitted following M. Patients receiving T-DM1 began RT after 12 weeks of therapy and received RT concurrently with T-DM1; patients receiving TH began RT after T was complete and received RT concurrently with H. RT records were retrospectively reviewed to determine the fields, doses, and fraction size. Acute RT toxicity (CTC AE v4.0) was determined by two radiation oncologists; discrepancies were adjudicated by a third oncologist.Results: Four hundred ninety-seven patients initiated protocol therapy (383 T-DM1, 114 TH). 75.1% had hormone receptor positive disease (HR+), and 3.8% micrometastatic nodal involvement. Among the 303 BCS patients, 41.7% in the T-DM1 arm and 42.6% of TH patients were treated with hypofractionation (HYPO; fraction size ≥ 2.5 Gy); nodal RT was given to 1.3% and 0%, respectively. 3.4% and 2.9% received partial breast irradiation (PBI). Of the 188 M patients, 4.3% underwent RT (all conventional fractionation (fx)). Grade 2 acute skin toxicity was seen in 33.2% of patients on the T-DM1 arm (20.3% HYPO), and 23.2% on the TH arm (25.0% HYPO). Only 2 patients experienced a grade 3 skin toxicity, both on the T-DM1 arm. One had conventional fx and the other HYPO. Five patients experienced pneumonitis following RT (T-DM1: n = 4, 1.0%; TH: n = 1, 0.9%). Two patients had grade 3 pneumonitis (both HYPO; 1 T-DM1, 1 TH); the remaining three patients had grade 2 pneumonitis (all T-DM1 and conventional fx). Two patients had an ipsilateral rib fracture following RT (one received TH, the other T-DM1). Three-year iDFS was 97.8% for the T-DM1 arm (95% CI 96.3-99.3), and 93.4% for TH (95% CI 88.7-98.2). Among the 18 iDFS events, 7 isolated local recurrences were seen (2 with T-DM1, 5 with TH; 5/7 HR+).Conclusion: RT was well-tolerated when given concurrently with either T-DM1 or H, regardless of fractionation. Local recurrences were unlikely, attesting to the efficacy of highly effective HER2-directed therapy with RT, and suggesting opportunities for future study of RT de-escalation. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 152496894
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bellon%2C+J%2ER%2E%22">Bellon, J.R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tayob%2C+N%2E%22">Tayob, N.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burstein%2C+H%2EJ%2E%22">Burstein, H.J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Partridge%2C+A%2E%22">Partridge, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Demeo%2C+M%2EK%2E%22">Demeo, M.K.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tralins%2C+J%2E%22">Tralins, J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yang%2C+D%2ED%2E%22">Yang, D.D.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dang%2C+C%2E%22">Dang, C.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Isakoff%2C+S%2EJ%2E%22">Isakoff, S.J.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yardley%2C+D%2E%22">Yardley, D.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Valero%2C+V%2E%22">Valero, V.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Winer%2C+E%2E%22">Winer, E.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krop%2C+I%2E%22">Krop, I.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tolaney%2C+S%2E%22">Tolaney, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22">International Journal of Radiation Oncology, Biology, Physics</searchLink>. 2021 Supplement, Vol. 111 Issue 3, pS34-S34. 1p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22HER2+positive+breast+cancer%22">HER2 positive breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Hormone+receptors%22">Hormone receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Breast+cancer%22">Breast cancer</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Purpose/objective(s): </bold>Anti-HER2 therapy improves local control in women with HER2+ breast cancer. This retrospective analysis evaluates the efficacy and safety of radiation therapy (RT) across a range of RT doses, targets, and schedules among patients receiving T-DM1 and TH in the ATEMPT trial.<bold>Materials/methods: </bold>The ATEMPT trial is a prospective randomized phase II study of adjuvant ado-trastuzumab emtansine (T-DM1) vs. paclitaxel (T) and trastuzumab (H) following either mastectomy (M) or breast conserving surgery (BCS) in women with stage I HER2+ breast cancer. Eligible patients had T1N0 or T1N1mi HER2+ disease (3+ IHC or FISH ≥ 2) and were randomized 3:1 to either T-DM1 (3.6 mg/kg every three weeks x 17 treatments) or T (80 mg/m2 weekly for 3 weeks), H (4 mg/kg first week, then 2 mg/kg weekly x 12 weeks during T; then 6 mg/kg every 3 weeks x 39 weeks). Breast RT was required following BCS and permitted following M. Patients receiving T-DM1 began RT after 12 weeks of therapy and received RT concurrently with T-DM1; patients receiving TH began RT after T was complete and received RT concurrently with H. RT records were retrospectively reviewed to determine the fields, doses, and fraction size. Acute RT toxicity (CTC AE v4.0) was determined by two radiation oncologists; discrepancies were adjudicated by a third oncologist.<bold>Results: </bold>Four hundred ninety-seven patients initiated protocol therapy (383 T-DM1, 114 TH). 75.1% had hormone receptor positive disease (HR+), and 3.8% micrometastatic nodal involvement. Among the 303 BCS patients, 41.7% in the T-DM1 arm and 42.6% of TH patients were treated with hypofractionation (HYPO; fraction size ≥ 2.5 Gy); nodal RT was given to 1.3% and 0%, respectively. 3.4% and 2.9% received partial breast irradiation (PBI). Of the 188 M patients, 4.3% underwent RT (all conventional fractionation (fx)). Grade 2 acute skin toxicity was seen in 33.2% of patients on the T-DM1 arm (20.3% HYPO), and 23.2% on the TH arm (25.0% HYPO). Only 2 patients experienced a grade 3 skin toxicity, both on the T-DM1 arm. One had conventional fx and the other HYPO. Five patients experienced pneumonitis following RT (T-DM1: n = 4, 1.0%; TH: n = 1, 0.9%). Two patients had grade 3 pneumonitis (both HYPO; 1 T-DM1, 1 TH); the remaining three patients had grade 2 pneumonitis (all T-DM1 and conventional fx). Two patients had an ipsilateral rib fracture following RT (one received TH, the other T-DM1). Three-year iDFS was 97.8% for the T-DM1 arm (95% CI 96.3-99.3), and 93.4% for TH (95% CI 88.7-98.2). Among the 18 iDFS events, 7 isolated local recurrences were seen (2 with T-DM1, 5 with TH; 5/7 HR+).<bold>Conclusion: </bold>RT was well-tolerated when given concurrently with either T-DM1 or H, regardless of fractionation. Local recurrences were unlikely, attesting to the efficacy of highly effective HER2-directed therapy with RT, and suggesting opportunities for future study of RT de-escalation. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=152496894
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ijrobp.2021.07.103
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S34
    Subjects:
      – SubjectFull: HER2 positive breast cancer
        Type: general
      – SubjectFull: Hormone receptors
        Type: general
      – SubjectFull: Breast cancer
        Type: general
    Titles:
      – TitleFull: Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bellon, J.R.
      – PersonEntity:
          Name:
            NameFull: Tayob, N.
      – PersonEntity:
          Name:
            NameFull: Burstein, H.J.
      – PersonEntity:
          Name:
            NameFull: Partridge, A.
      – PersonEntity:
          Name:
            NameFull: Demeo, M.K.
      – PersonEntity:
          Name:
            NameFull: Tralins, J.
      – PersonEntity:
          Name:
            NameFull: Yang, D.D.
      – PersonEntity:
          Name:
            NameFull: Dang, C.
      – PersonEntity:
          Name:
            NameFull: Isakoff, S.J.
      – PersonEntity:
          Name:
            NameFull: Yardley, D.
      – PersonEntity:
          Name:
            NameFull: Valero, V.
      – PersonEntity:
          Name:
            NameFull: Winer, E.
      – PersonEntity:
          Name:
            NameFull: Krop, I.
      – PersonEntity:
          Name:
            NameFull: Tolaney, S.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 11
              Text: 2021 Supplement
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 03603016
          Numbering:
            – Type: volume
              Value: 111
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: International Journal of Radiation Oncology, Biology, Physics
              Type: main
ResultId 1